CRISM Therapeutics Corporation (AIM:CRTX)

CRISM Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	-	0.05	-	-	-
Other Revenue	0.03	-	-	-	-
Revenue	0.03	0.05	-	-	-
Revenue Growth (YoY)	-44.44%	-	-	-	-
Cost of Revenue	0	0.03	-	-	-
Gross Profit	0.02	0.01	-	-	-
Selling, General & Admin	0.72	0.14	1.85	1.32	2.26
Research & Development	0.17	0.03	-	-	-
Operating Expenses	0.9	0.18	1.85	1.32	2.26
Operating Income	-0.88	-0.17	-1.85	-1.32	-2.26
Interest Expense	-0.01	-0.03	-	-	-0.01
Interest & Investment Income	-	-	-	-	0.15
Currency Exchange Gain (Loss)	-	-	-	-0	0
Other Non Operating Income (Expenses)	-	-	-	-	-0.07
EBT Excluding Unusual Items	-0.89	-0.2	-1.85	-1.32	-2.18
Asset Writedown	-	-	-	-	0.31
Other Unusual Items	0.3	-	-0.32	-	-0.08
Pretax Income	-0.59	-0.2	-2.16	-1.32	-1.95
Income Tax Expense	-	-0.01	-	-	-
Earnings From Continuing Operations	-0.59	-0.2	-2.16	-1.32	-1.95
Earnings From Discontinued Operations	-0.01	-	-0.34	0.43	-
Net Income	-0.61	-0.2	-2.5	-0.89	-1.95
Net Income to Common	-0.61	-0.2	-2.5	-0.89	-1.95
Shares Outstanding (Basic)	32	0	9	9	7
Shares Outstanding (Diluted)	32	0	9	9	7
Shares Change (YoY)	201033.86%	-99.82%	0.85%	28.82%	45.57%
EPS (Basic)	-0.02	-12.25	-0.29	-0.10	-0.29
EPS (Diluted)	-0.02	-12.25	-0.29	-0.10	-0.29
Free Cash Flow	-0.93	-0.1	-2.92	-1.67	-2.02
Free Cash Flow Per Share	-0.03	-6.13	-0.34	-0.19	-0.30
Gross Margin	84.00%	28.89%	-	-	-
Operating Margin	-3520.00%	-377.78%	-	-	-
Profit Margin	-2428.00%	-435.56%	-	-	-
Free Cash Flow Margin	-3732.00%	-217.78%	-	-	-
EBITDA	-0.86	-0.15	-1.62	-1.12	-2.26
D&A For EBITDA	0.02	0.02	0.23	0.2	0
EBIT	-0.88	-0.17	-1.85	-1.32	-2.26

Source: S&P Global Market Intelligence. Standard template. Financial Sources.